Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)

Tatsunori Shimoi, Akihiko Shimomura, Tadahiko Shien, Yukari Uemura, Hiroaki Kato, Masahiro Kitada, Tatsuya Toyama, Tomohiko Aihara, Hirofumi Mukai

Research output: Contribution to journalArticle

Abstract

Background: This is a randomized, multicenter, open-label, Phase II study designed to evaluate the efficacy of everolimus added to continuous aromatase inhibitor (AI) administration in patients who had maintained stable disease or a better response for at least 5 months. Patients and methods: Patients will be randomized to everolimus and standard therapy groups (1:1 ratio). In the everolimus group, patients will receive everolimus in addition to the AI agent. The standard therapy group will continue AI alone treatment. The primary endpoint is progression-free survival. Target accrual is 130 patients with a two-sided type I error rate of 10% and 80% power to detect 35% risk reduction. Conclusion: The Chloe trial will provide important information about the efficacy and safety of adding everolimus to AI in patients with estrogen receptor-positive and human epidermal growth factor 2-negative metastatic breast cancer.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalOpen Access Journal of Clinical Trials
Volume10
DOIs
Publication statusPublished - Feb 16 2018

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
Group Psychotherapy
Therapeutics
Risk Reduction Behavior
Epidermal Growth Factor
Estrogen Receptors
Disease-Free Survival
Everolimus
Safety

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Everolimus
  • Hormone receptor-positive

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Pharmacology (medical)

Cite this

Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial). / Shimoi, Tatsunori; Shimomura, Akihiko; Shien, Tadahiko; Uemura, Yukari; Kato, Hiroaki; Kitada, Masahiro; Toyama, Tatsuya; Aihara, Tomohiko; Mukai, Hirofumi.

In: Open Access Journal of Clinical Trials, Vol. 10, 16.02.2018, p. 13-18.

Research output: Contribution to journalArticle

Shimoi, Tatsunori ; Shimomura, Akihiko ; Shien, Tadahiko ; Uemura, Yukari ; Kato, Hiroaki ; Kitada, Masahiro ; Toyama, Tatsuya ; Aihara, Tomohiko ; Mukai, Hirofumi. / Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial). In: Open Access Journal of Clinical Trials. 2018 ; Vol. 10. pp. 13-18.
@article{51ced17096a84541862b9e7c3dd860a9,
title = "Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)",
abstract = "Background: This is a randomized, multicenter, open-label, Phase II study designed to evaluate the efficacy of everolimus added to continuous aromatase inhibitor (AI) administration in patients who had maintained stable disease or a better response for at least 5 months. Patients and methods: Patients will be randomized to everolimus and standard therapy groups (1:1 ratio). In the everolimus group, patients will receive everolimus in addition to the AI agent. The standard therapy group will continue AI alone treatment. The primary endpoint is progression-free survival. Target accrual is 130 patients with a two-sided type I error rate of 10{\%} and 80{\%} power to detect 35{\%} risk reduction. Conclusion: The Chloe trial will provide important information about the efficacy and safety of adding everolimus to AI in patients with estrogen receptor-positive and human epidermal growth factor 2-negative metastatic breast cancer.",
keywords = "Aromatase inhibitor, Breast cancer, Everolimus, Hormone receptor-positive",
author = "Tatsunori Shimoi and Akihiko Shimomura and Tadahiko Shien and Yukari Uemura and Hiroaki Kato and Masahiro Kitada and Tatsuya Toyama and Tomohiko Aihara and Hirofumi Mukai",
year = "2018",
month = "2",
day = "16",
doi = "10.2147/OAJCT.S155706",
language = "English",
volume = "10",
pages = "13--18",
journal = "Open Access Journal of Clinical Trials",
issn = "1179-1519",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)

AU - Shimoi, Tatsunori

AU - Shimomura, Akihiko

AU - Shien, Tadahiko

AU - Uemura, Yukari

AU - Kato, Hiroaki

AU - Kitada, Masahiro

AU - Toyama, Tatsuya

AU - Aihara, Tomohiko

AU - Mukai, Hirofumi

PY - 2018/2/16

Y1 - 2018/2/16

N2 - Background: This is a randomized, multicenter, open-label, Phase II study designed to evaluate the efficacy of everolimus added to continuous aromatase inhibitor (AI) administration in patients who had maintained stable disease or a better response for at least 5 months. Patients and methods: Patients will be randomized to everolimus and standard therapy groups (1:1 ratio). In the everolimus group, patients will receive everolimus in addition to the AI agent. The standard therapy group will continue AI alone treatment. The primary endpoint is progression-free survival. Target accrual is 130 patients with a two-sided type I error rate of 10% and 80% power to detect 35% risk reduction. Conclusion: The Chloe trial will provide important information about the efficacy and safety of adding everolimus to AI in patients with estrogen receptor-positive and human epidermal growth factor 2-negative metastatic breast cancer.

AB - Background: This is a randomized, multicenter, open-label, Phase II study designed to evaluate the efficacy of everolimus added to continuous aromatase inhibitor (AI) administration in patients who had maintained stable disease or a better response for at least 5 months. Patients and methods: Patients will be randomized to everolimus and standard therapy groups (1:1 ratio). In the everolimus group, patients will receive everolimus in addition to the AI agent. The standard therapy group will continue AI alone treatment. The primary endpoint is progression-free survival. Target accrual is 130 patients with a two-sided type I error rate of 10% and 80% power to detect 35% risk reduction. Conclusion: The Chloe trial will provide important information about the efficacy and safety of adding everolimus to AI in patients with estrogen receptor-positive and human epidermal growth factor 2-negative metastatic breast cancer.

KW - Aromatase inhibitor

KW - Breast cancer

KW - Everolimus

KW - Hormone receptor-positive

UR - http://www.scopus.com/inward/record.url?scp=85046673541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046673541&partnerID=8YFLogxK

U2 - 10.2147/OAJCT.S155706

DO - 10.2147/OAJCT.S155706

M3 - Article

VL - 10

SP - 13

EP - 18

JO - Open Access Journal of Clinical Trials

JF - Open Access Journal of Clinical Trials

SN - 1179-1519

ER -